Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression

Biol Psychiatry. 2015 Feb 1;77(3):e19-e20. doi: 10.1016/j.biopsych.2014.06.021. Epub 2014 Jul 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / therapeutic use*
  • Biomarkers, Pharmacological / blood
  • Depressive Disorder, Major / blood
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Treatment-Resistant / blood
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Humans
  • Inpatients
  • Interleukin-1beta / blood
  • Interleukin-6 / blood*
  • Ketamine / therapeutic use*
  • Kynurenine / blood
  • Psychiatric Status Rating Scales
  • Treatment Outcome
  • Tryptophan / blood
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Antidepressive Agents
  • Biomarkers, Pharmacological
  • IL1B protein, human
  • IL6 protein, human
  • Interleukin-1beta
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Kynurenine
  • Ketamine
  • Tryptophan